Hormonal
Second-generation obesity medications (semaglutide 2.4 mg and tirzepatide) achieve clinically significant weight loss (≥15% body weight) and treat or prevent obesity-related complications, establishing a complications-centric approach to care.
If you have obesity, especially with complications like diabetes or heart disease, second-generation medications like semaglutide or tirzepatide are now available that can help you lose 15% or more of your body weight. This level of weight loss is significant enough to improve or prevent many serious health issues. The main barrier is often cost and insurance coverage, so advocate for your access to these treatments as a medical necessity.
Semaglutide and tirzepatide have recently been approved for obesity and found to achieve ≥15% weight loss in clinical trials. These drugs have been referred to as second-generation medications because the unprecedented degree of weight loss they afford is sufficient to treat or prevent a broad array of obesity complications and related diseases.
Why this rating
Based on multiple phase 2 and 3 clinical trials cited (e.g., SURMOUNT-1, SELECT), showing robust, reproducible results.
Source
Future Medications for Obesity and Clinical Implications
W. Timothy Garvey · Diabetes Spectrum · 2024
DOI 10.2337/dsi24-0004
More from this paper
- Dual and triple receptor agonists (e.g., tirzepatide, retatrutide, survodutide) demonstrate second-generation efficacy (≥15% weight loss) in clinical trials, offering expanded treatment options for obesity.Good
- Preservation of skeletal muscle mass is a critical consideration in obesity treatment with second-generation medications, and new drugs (e.g., bimagrumab) are being developed to block muscle loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →